Neurocrine Bio. stock price target raised to $195 from $188 at UBS
PositiveFinancial Markets

Neurocrine Biosciences has received a boost as UBS has raised its stock price target from $188 to $195. This adjustment reflects growing confidence in the company's potential and could attract more investors. Such positive news is significant as it indicates a favorable outlook for Neurocrine's future performance in the market.
— Curated by the World Pulse Now AI Editorial System